SCHEMBL10136673

SCHEMBL10136673

COC(=O)c1cccc2c1nc(Cl)c1cnccc12

nearest known ligand 0.63

Predicted protein targets (top 16)

geneUniProtsupporting neighboursconfidence
PIM1 P11309 15/20 0.63
PIM2 Q9P1W9 15/20 0.63
BAD Q92934 8/20 0.48
FLT3 P36888 3/20 0.48
CSNK2A2 P19784 1/20 0.48
CSNK2B P67870 1/20 0.48
PIM3 Q86V86 1/20 0.47
PKN1 Q16512 1/20 0.45
PKN2 Q16513 1/20 0.45
KDM4E B2RXH2 2/20 0.43
ALDH1A1 P00352 1/20 0.43
GLA P06280 1/20 0.43
GAA P10253 1/20 0.43
MAPK8 P45983 1/20 0.43
MAPK9 P45984 1/20 0.43
MAPK10 P53779 1/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2688734 0.95 PIM1 (0.66) PIM1PIM2BADFLT3CSNK2A2
SCHEMBL10169351 0.83 PIM1 (0.61) PIM1PIM2BADFLT3CSNK2A2
SCHEMBL10136670 0.81 PIM1 (0.49) PIM1PIM2BADFLT3CSNK2A2
SCHEMBL12768367 0.79 MAPK8 (0.46) PIM1PIM2PKN1PKN2KDM4E
SCHEMBL2687706 0.78 PIM1 (1.00) PIM1PIM2BADFLT3CSNK2A2
SCHEMBL10134645 0.77 PIM1 (0.79) PIM1PIM2BADFLT3CSNK2A2
SCHEMBL528027 0.77 KDM4E (0.50) PIM1PIM2KDM4EALDH1A1GAA
SCHEMBL10136651 0.77 PIM1 (0.52) PIM1PIM2BADFLT3CSNK2A2
SCHEMBL29802386 0.75 KDM4E (0.53) PIM1PIM2PKN1PKN2KDM4E
SCHEMBL21801215 0.75 MAPK8 (0.53) PIM1PIM2PKN1PKN2KDM4E

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20120208792-A1 PROTEIN KINASE MODULATORS CYLENE PHARMACEUTICALS, INC. (US) 2012-08-16 US disclosed
US-20120208792-A1 PROTEIN KINASE MODULATORS CYLENE PHARMACEUTICALS, INC. (US) 2012-08-16 US disclosed
US-8168651-B2 Protein kinase modulators CYLENE PHARMACEUTICALS, INC. (US) 2012-05-01 US disclosed
US-8168651-B2 Protein kinase modulators CYLENE PHARMACEUTICALS, INC. (US) 2012-05-01 US disclosed
US-20090239859-A1 PROTEIN KINASE MODULATORS SENHWA BIOSCIENCES, INC. (TW) 2009-09-24 US disclosed
US-20090239859-A1 PROTEIN KINASE MODULATORS SENHWA BIOSCIENCES, INC. (TW) 2009-09-24 US disclosed
WO-2009108912-A1 PROTEIN KINASE MODULATORS CYLENE PHARMACEUTICALS, INC. (US) 2009-09-03 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120208792-A1 PROTEIN KINASE MODULATORS PIM1, PIM2, PIM3 PIM1 1/4885PIM2 2/4885BAD 892/4885
US-20090239859-A1 PROTEIN KINASE MODULATORS PIM1, PIM2, PIM3 PIM1 1/4885PIM2 2/4885BAD 892/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.